BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 25476749)

  • 1. Significant reduction in end-stage liver diseases burden through the national viral hepatitis therapy program in Taiwan.
    Chiang CJ; Yang YW; Chen JD; You SL; Yang HI; Lee MH; Lai MS; Chen CJ
    Hepatology; 2015 Apr; 61(4):1154-62. PubMed ID: 25476749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. National antiviral treatment program and the incidence of hepatocellular carcinoma and associated mortality in Taiwan: a preliminary report.
    Chang CH; Lin JW; Wu LC; Liu CH; Lai MS
    Med Care; 2013 Oct; 51(10):908-13. PubMed ID: 23969591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High incidence of hepatocellular carcinoma in ESRD patients: caused by high hepatitis rate or 'uremia'? a population-based study.
    Hwang JC; Weng SF; Weng RH
    Jpn J Clin Oncol; 2012 Sep; 42(9):780-6. PubMed ID: 22782961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incomplete hepatitis B immunization, maternal carrier status, and increased risk of liver diseases: a 20-year cohort study of 3.8 million vaccinees.
    Chien YC; Jan CF; Chiang CJ; Kuo HS; You SL; Chen CJ
    Hepatology; 2014 Jul; 60(1):125-32. PubMed ID: 24497203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Nationwide Hepatitis B Vaccination and Antiviral Therapy Programs With End-Stage Liver Disease Burden in Taiwan.
    Chiang CJ; Jhuang JR; Yang YW; Zhuang BZ; You SL; Lee WC; Chen CJ
    JAMA Netw Open; 2022 Jul; 5(7):e2222367. PubMed ID: 35849394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in the incidence of hepatocellular carcinoma in boys and girls in Taiwan after large-scale hepatitis B vaccination.
    Lee CL; Hsieh KS; Ko YC
    Cancer Epidemiol Biomarkers Prev; 2003 Jan; 12(1):57-9. PubMed ID: 12540504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural history of chronic hepatitis B REVEALed.
    Chen CJ; Yang HI
    J Gastroenterol Hepatol; 2011 Apr; 26(4):628-38. PubMed ID: 21323729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study.
    Lai SW; Chen PC; Liao KF; Muo CH; Lin CC; Sung FC
    Am J Gastroenterol; 2012 Jan; 107(1):46-52. PubMed ID: 22085817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colchicine delays the development of hepatocellular carcinoma in patients with hepatitis virus-related liver cirrhosis.
    Arrieta O; Rodriguez-Diaz JL; Rosas-Camargo V; Morales-Espinosa D; Ponce de Leon S; Kershenobich D; Leon-Rodriguez E
    Cancer; 2006 Oct; 107(8):1852-8. PubMed ID: 16967451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles.
    Lee MH; Yang HI; Liu J; Batrla-Utermann R; Jen CL; Iloeje UH; Lu SN; You SL; Wang LY; Chen CJ;
    Hepatology; 2013 Aug; 58(2):546-54. PubMed ID: 23504622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
    Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
    J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of hepatobiliary disease in adults with severe alpha 1-antitrypsin deficiency (PiZZ): is chronic viral hepatitis B or C an additional risk factor for cirrhosis and hepatocellular carcinoma?
    Elzouki AN; Eriksson S
    Eur J Gastroenterol Hepatol; 1996 Oct; 8(10):989-94. PubMed ID: 8930564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis.
    Chiaramonte M; Stroffolini T; Vian A; Stazi MA; Floreani A; Lorenzoni U; Lobello S; Farinati F; Naccarato R
    Cancer; 1999 May; 85(10):2132-7. PubMed ID: 10326690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology, disease burden and outcomes of cirrhosis in a large secondary care hospital in South Auckland, New Zealand.
    Hsiang JC; Bai WW; Raos Z; Stableforth W; Upton A; Selvaratnam S; Gane EJ; Gerred SJ
    Intern Med J; 2015 Feb; 45(2):160-9. PubMed ID: 25371019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis.
    Kim SS; Hwang JC; Lim SG; Ahn SJ; Cheong JY; Cho SW
    Am J Gastroenterol; 2014 Aug; 109(8):1223-33. PubMed ID: 24890440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection.
    Hosaka T; Suzuki F; Kobayashi M; Seko Y; Kawamura Y; Sezaki H; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    Hepatology; 2013 Jul; 58(1):98-107. PubMed ID: 23213040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study.
    Chang MH; You SL; Chen CJ; Liu CJ; Lee CM; Lin SM; Chu HC; Wu TC; Yang SS; Kuo HS; Chen DS;
    J Natl Cancer Inst; 2009 Oct; 101(19):1348-55. PubMed ID: 19759364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
    Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
    Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan.
    Chen TH; Chen CJ; Yen MF; Lu SN; Sun CA; Huang GT; Yang PM; Lee HS; Duffy SW
    Int J Cancer; 2002 Mar; 98(2):257-61. PubMed ID: 11857416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viral hepatitis and hepatocellular carcinoma.
    Sallie R; Di Bisceglie AM
    Gastroenterol Clin North Am; 1994 Sep; 23(3):567-79. PubMed ID: 7989095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.